Cerebral ageing;Le vieillissement céréral

Revue de Geriatrie

Volumn 27, Issue 10, 2002, Pages 843-849

  Delacourte, André ^a  

^a INSERM   (France)

Author keywords

Alzheimer's disease; Cerebral aging; Degenerating process; Tau pathology

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; BRAIN MATURATION; DEGENERATIVE DISEASE; HUMAN; INTELLECTUAL IMPAIRMENT; REVIEW;

EID: 0036956222     PISSN: 03977927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Gély-Nargeot MC, et al. Effet du vieillissement cognitif sur les performances mnésiques. La Presse Médicale 2000;29:849-57.
2. Robert L. Le vieillissement. Belin CNRS Editions, 1994.
3. Section III. Senses:sensory cortices and primary afferent functions. Vision. Hearing. Chemical senses. Functional neurobiology of aging. Edited by Hof P, Mobbs CV. Academic Press 2001:495-655.
4. Lindenberger U. and PB. Baltes, Intellectual fonctionning in old and very old age: cross-sectionn al results from the Berlin aging study. Psychol Aging 1997;12:410-32.
5. Rivner MH, Swift TR, Malik K. Influence of age and height on nerve conduction. Muscle Nerve 2001;24:1134-41.
6. Morgan D. May P. Age-related changes in synaptic neurochemistry. Handbook of the biology of aging. Edited by Schneider EL, Rowe JW. Academic press, 1990. Third edition. 219-254.
7. Mishizen A, Ikonomovic M, Armstrong D. Glutamate receptors in aging and Alzheimer's disease. Functional neurobiology of aging. Edited by Hof P, Mobbs CV. Academic Press 2001:283-314.
8. Section. V. Homeostasis: hypothalamus and related systems. Functional neurobiology of aging. Edited by Hof P, Mobbs CV. Academic Press 2001:739-937.
9. Hartley AA. Attention. The handbook of aging and cognition. Craik F, Salthouse T.A Eds). Hillsdale N.J., Lauwrence Erlbaum Associates, 1992:3-50.
10. Glenner G.G., et al. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984;2:357-69.
11. Wisniewski T, Ghiso J, Frangione B. Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis 1997;4:313-28.
12. Buee L, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.
13. Delacourte A, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002;59(August).
14. Delacourte A, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999;52:1158-65.
15. Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett 1993;153:131-5.
16. Braak H. Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7.
17. Duyckaerts C, et al. The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study. J Neural Transm Suppl 1998;53:119-26.
18. Sergeant N, et al. Progressive decrease of APP carboxy-terminal fragments, associated with tau pathology stages, in Alzheimer's disease. J Neurochem 2002;81:663-72.
19. Gotz J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-5.
20. Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci 1999;354:1101-18.
21. Flament S, et al. Characterization of two pathological tau protein, variants in Alzheimer brain cortices. J Neurol Sci 1989;92:133-41.